RMD (ResMed Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by RMD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-10 | Michael J. Farrell | Chairman and CEO | MIXED | — | — |
| 2026-09-04 | PETER C FARRELL | Director | Sell | — | — |
| 2026-08-11 | Michael J. Farrell | Chairman and CEO | MIXED | — | — |
| 2026-08-06 | PETER C FARRELL | Director | Sell | — | — |
| 2026-08-06 | PETER C FARRELL | Director | Sell | — | — |
| 2026-07-09 | Michael J. Farrell | Chairman and CEO | MIXED | — | — |
| 2026-06-09 | Michael J. Farrell | Chairman and CEO | MIXED | — | — |
| 2026-06-03 | Michael J Rider | Global General Counsel | F | — | — |
| 2026-05-11 | Michael J. Farrell | Chairman and CEO | MIXED | — | — |
| 2026-05-04 | Brett Sandercock | Chief Financial Officer | — | — | — |
| 2026-04-09 | Michael J. Farrell | Chairman and CEO | MIXED | — | — |
| 2026-04-03 | Brett Sandercock | Chief Financial Officer | Sell | — | — |
| 2026-04-02 | PETER C FARRELL | Director | Sell | — | — |
| 2026-03-11 | Michael J. Farrell | Chairman and CEO | MIXED | — | — |
| 2026-03-05 | PETER C FARRELL | Director | Sell | — | — |
| 2026-03-03 | Brett Sandercock | Chief Financial Officer | Sell | — | — |
| 2026-02-10 | Michael J. Farrell | Chairman and CEO | MIXED | — | — |
| 2026-02-06 | Michael J Rider | Global General Counsel | Sell | — | — |
| 2026-02-06 | PETER C FARRELL | Director | Sell | — | — |
| 2026-02-03 | Brett Sandercock | Chief Financial Officer | Sell | — | — |
| 2026-01-09 | PETER C FARRELL | Director | Sell | — | — |
| 2026-01-08 | Michael J. Farrell | Chairman and CEO | MIXED | — | — |
| 2026-01-05 | Michael J Rider | Global General Counsel | Sell | — | — |
| 2026-01-05 | Brett Sandercock | Chief Financial Officer | Sell | — | — |
| 2025-12-09 | Michael J. Farrell | Chairman and CEO | MIXED | — | — |
| 2025-12-04 | PETER C FARRELL | Director | Sell | — | — |
| 2025-12-02 | Brett Sandercock | Chief Financial Officer | Sell | — | — |
| 2025-12-02 | Michael J Rider | Global General Counsel | Sell | — | — |
| 2025-11-26 | Nicole Mowad-Nassar | Director | A | — | — |
| 2025-11-26 | Jan De Witte | Director | Sell | — | — |
| 2025-11-26 | PETER C FARRELL | Director | A | — | — |
| 2025-11-26 | Michael J. Farrell | Chairman and CEO | A | — | — |
| 2025-11-24 | PETER C FARRELL | Director | A | — | — |
| 2025-11-24 | Jan De Witte | Director | A | — | — |
| 2025-11-24 | Christopher DelOrefice | Director | A | — | — |
| 2025-11-24 | Michael J. Farrell | Chairman and CEO | MIXED | — | — |
| 2025-11-24 | Brett Sandercock | Chief Financial Officer | A | — | — |
| 2025-11-24 | RONALD R TAYLOR | Director | A | — | — |
| 2025-11-24 | Carol Burt | Director | A | — | — |
| 2025-11-24 | Karen Drexler | Director | A | — | — |
| 2025-11-24 | Harjit Gill | Director | A | — | — |
| 2025-11-24 | Desney Tan | Director | A | — | — |
| 2025-11-24 | Nicole Mowad-Nassar | Director | A | — | — |
| 2025-11-24 | John Hernandez | Director | A | — | — |
| 2025-11-24 | Justin Leong | Chief Product Officer | A | — | — |
| 2025-11-21 | RICHARD SULPIZIO | Director | — | — | — |
| 2025-11-18 | PETER C FARRELL | Director | MIXED | — | — |
| 2025-11-14 | Harjit Gill | Director | F | — | — |
| 2025-11-13 | Michael J Rider | Global General Counsel | F | — | — |
| 2025-11-13 | Jan De Witte | Director | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 641,000 | — |
| — | Chairman and CEO | 473,337 | — |
| — | Special Advisor | 264,375 | — |
| — | Director | 247,537 | — |
| — | Director | 241,736 | — |
| — | Chief Administrative Officer | 89,729 | — |
| — | Former President-ResMed Europe | 84,633 | — |
| — | Chief Financial Officer | 83,495 | — |
| — | President, Sleep Business | 76,721 | — |
| — | Chief Executive Officer | 56,921 | — |
| — | President - Europe | 52,143 | — |
| — | Director | 51,803 | — |
| — | Director | 48,000 | — |
| — | COO Europe | 40,000 | — |
| — | Chief Product Officer | 29,028 | — |
| — | President, SaaS Business | 26,731 | — |
| — | Director | 24,771 | — |
| — | President, RC Business | 22,982 | — |
| — | Chief Commercial Officer, SaaS | 19,430 | — |
| — | Director | 18,816 | — |
| — | Director | 18,356 | — |
| — | Director | 17,796 | — |
| — | Director | 13,823 | — |
| — | Pres. Global Innovation and Op | 13,684 | — |
| — | Director | 10,940 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RMD quote page; the site-wide leaderboard is on the insider transactions hub.